X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALTB-268 is an antibody injection which works by targeting PSGL-1, it is currently being investigated for the treatment of an IBD disease, Ulcerative Colitis.
Lead Product(s): ALTB-268
Therapeutic Area: Gastroenterology Product Name: ALTB-268
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
ALTB-268 is a tetravalent PSGL-1 agonist antibody that acts as an immune checkpoint enhancer (ICE) to preferentially downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Lead Product(s): ALTB-268
Therapeutic Area: Gastroenterology Product Name: ALTB-268
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
ALTB-268 is a tetravalent PSGL-1 agonist antibody that acts as an immune checkpoint enhancer (ICE) to preferentially downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Lead Product(s): ALTB-268
Therapeutic Area: Gastroenterology Product Name: ALTB-268
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulates chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Lead Product(s): ALTB-268
Therapeutic Area: Gastroenterology Product Name: ALTB-268
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
ALTB-168 (neihulizumab) is an immune checkpoint enhancer that regulates T cell homeostasis. This agonist antibody maintains T cell homeostasis by downregulating of activated T cells, potentially sparing resting T cells and early-activated T cells thus controlling inflammation.
Lead Product(s): Neihulizumab
Therapeutic Area: Gastroenterology Product Name: ALTB-168
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
The company will share development plans for next generation immune checkpoint enhancer, ALTB-268, bearing the same mechanism of action with increased potency for subcutaneous administration in ulcerative colitis patients.
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: ALTB-168
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Lead Product(s): ALTB-268
Therapeutic Area: Gastroenterology Product Name: ALTB-268
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Neihulizumab (ALTB-168) is an immune checkpoint enhancer that regulates T cell homeostasis, unique mechanism of action of this agonist antibody maintains T cell homeostasis by preferentially inducing downregulation of activated T cells.
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: ALTB-168
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
ALTB-168 (neihulizumab), is immune checkpoint agonist antibody that regulates T cell homeostasis, unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death.
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: ALTB-168
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Neihulizumab, is a first-generation immune checkpoint regulator targeting PSGL-1 that is capable of selectively depleting chronically activated T cells and achieving natural immune homeostasis against immunological diseases.
Lead Product(s): Neihulizumab
Therapeutic Area: Immunology Product Name: AbGn-168H
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
